Arbeitsgruppe Pankreaskarzinom - Studien
| Pankreaskarzinom - adjuvante Therapie |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0111/ass: A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine alone (Arm G) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH) | ||||
| ---in Rekrutierung --- | ||||
| Metastasiertes Pankreaskarzinoms - Erstlinientherapie |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0317/ass: A multicenter randomized phase II/III study to determine the optimal first line chemotherapy regimen in medically fit patients diagnosed with metastatic pancreatic cancer (FOOTPATH) |
||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | Für weitere Zentren offen |
zur Studie | ||
| AIO-PAK-0219: Intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled phase 3 trial (METAPANC) | ||||
| ---in Vorbereitung--- | ||||
| Pankreaskarzinom – palliative Therapie, 2nd-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0216: Second- line therapy with Nal-IRI after failure of
gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of
first-line therapy - PREDICT |
||||
| ---in Rekrutierung--- | ||||
| Pankreaskarzinom – palliative Therapie, 1st-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0114: Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study (ALPACA) | ||||
| ---in Rekrutierung--- | ||||
| Pankreaskarzinom – palliative Therapie: Phase 1-Studie |
| AIO-Studie | zur Studie | |||
| AIO-PAK-0117: Phase I feasibility study of nab-paclitaxel and gemcitabine in patients with matastatic prancreatic cancer and cholestatic hyperbilirubinemia (PANCHO) |
||||
| ---in Vorbereitung--- | ||||
| AIO-assoziierte Studie | für weitere Zentren offen | zur Studie | ||
| AIO-PAK-0119/ass: TAS-102 in Kombination mit Nab-Paclitaxel in der Erstlinientherapie des fortgeschrittenen Pankreaskarzinoms (Phase 1b) (CONKO 010) |
||||
| ---in Vorbereitung--- | ||||
| Pancreatic Ductal Adenocarcinoma / metastatic disease (stage IV) |
| AIO-Studie | zur Studie | |||
| AIO-PAK-0118: A multi-center, phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. (SEPION) |
||||
| ---in Vorbereitung--- | ||||
| Metastasiertes Adenokarzinom des Pankreas, Zweit- und Drittlinie |
| AIO-Studie | für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-PAK-0116: A health service research study to
investigate survival of metastatic pancreatic cancer patients after sequential
chemotherapy: An AIO phase II cross over trial (PANTHEON) |
||||
| ---in Rekrutierung--- | ||||
| Local begrenztes, inoperables Pankreaskarzinom |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie - CONKO-007 | ||||
| ---in Rekrutierung--- | ||||
| Pankreaskarzinom - Operable Patienten |
| AIO-assoziierte Studie | zur Studie | |||
| AIO-YMO/PAK-0218/ass - PROJECTION - Prognostic role of circulating tumor DNA in resectable pancreatic cancer | ||||
| ---in Vorbereitung--- | ||||
| Registerstudie |
| AIO-Studie | für weitere Zentren offen |
zur Studie | ||
| AIO-YMO/PAK-0215 Eine multizentrische Registerstudie zur Erfassung klinischer, epidemiologischer und biologischer Parameter beim duktalen Adenokarzinom des Pankreas (PDAC, PaCaReg) | ||||
| ---in Rekrutierung--- | ||||
LETZTE AKTUALISIERUNG DIESER SEITE AM: 08.05.2020 |